Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy-Reference-Cited by-同舟云学术

Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy

Published:2007-05-01 Issue:9 Volume:109 Page:1821-1828
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Chen Yuh-Min,Liu Jacqueline Ming,Chou Teh-Ying,Perng Reury-Perng,Tsai Chun-Ming,Whang-Peng Jacqueline

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference24 articles.

1. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

3. American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003

4. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

5. Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer;American Journal of Clinical Oncology;2024-09-11

2. Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis;Clinics;2023-01

3. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients;Lung Cancer;2018-09

4. A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation;Oncology Reports;2018-06-18

5. Gefitinib for advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2018-01-16